767286-87-3

Usage

Uses

Used in Pharmaceutical Research and Development:
4-(3-(Piperidin-1-yl)propoxy)benzoic acid is used as a building block in the synthesis of various organic compounds for pharmaceutical applications. Its structural features may contribute to the development of new drugs with potential therapeutic benefits.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(3-(Piperidin-1-yl)propoxy)benzoic acid is used as a starting material for the design and synthesis of novel compounds with potential pharmacological activities. Its unique structure allows for the exploration of new chemical entities that could address unmet medical needs.
Used in Drug Discovery:
4-(3-(Piperidin-1-yl)propoxy)benzoic acid is utilized in drug discovery research to identify and develop new therapeutic agents. Its potential pharmacological properties make it a valuable candidate for further investigation and optimization in the quest for innovative medications.
Used in Chemical Synthesis:
In the chemical synthesis industry, 4-(3-(Piperidin-1-yl)propoxy)benzoic acid is used as a key intermediate in the production of a variety of organic compounds. Its versatility in forming different chemical entities makes it a valuable component in the synthesis of complex organic molecules.

Upstream product

• 69076-29-5 4-(3-chloropropoxy)benzoic acid methyl ester 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 1258290-15-1 (5-(benzyloxy)-4-oxo-4H-pyran-2-yl)methyl 4-(3-(piperidin-1-yl)propoxy)benzoate 
• 752202-08-7 4-[3-(1-piperidinyl)propyloxy]benzoyl chloride 
• 1334335-21-5 C₁₇H₂₄N₂O₂ 
• 685871-24-3 4-(4-(3-(piperidin-1-yl)propoxy)benzoyl)piperazin-2-one 
• 912943-63-6 N-(5-{4-[3-(1-Ethyl-propyl)-ureido]-2-methoxy-phenoxy}-thiazol-2-yl)-4-(3-piperidin-1-yl-propoxy)-benzamide 

Relevant academic research and scientific papers

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Novel and highly potent histamine H3 receptor ligands. Part 1: Withdrawing of hERG activity

Pre-clinical investigation of some aryl-piperidinyl ether histamine H3 receptor antagonists revealed a strong hERG binding. To overcome this issue, we have developed a QSAR model specially dedicated to H3 receptor ligands. This model was designed to be di

Kojic acid derivatives as histamine H3 receptor ligands

The histamine H3 receptor (H3R) is a promising target in the development of new compounds for the treatment of mainly centrally occurring diseases. However, emerging novel therapeutic concepts have been introduced and some indications in the H3R field, e.g. migraine, pain or allergic rhinitis, might take advantage of peripherally acting ligands. In this work, kojic acid-derived structural elements were inserted into a well established H3R antagonist/inverse agonist scaffold to investigate the bioisosteric potential of γ-pyranones with respect to the different moieties of the H3R pharmacophore. The most affine compounds showed receptor binding in the low nanomolar concentration range. Evaluation and comparison of kojic acid-containing ligands and their corresponding phenyl analogues (3-7) revealed that the newly integrated scaffold greatly influences chemical properties (S Log P, topological polar surface area (tPSA)) and hence, potentially modifies the pharmacokinetic profile of the different derivatives. Benzyl-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)methanamine ligands 3 and 4 belong to the centrally acting diamine-based class of H3R antagonist/inverse agonist, whereas kojic acid analogues 6 and 7 might act peripherally. The latter compounds state promising lead structures in the development of H3R ligands with a modified profile of action.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.